CN102579548A - Frankincense-myrrh compound volatile oil and its preparation method and use - Google Patents
Frankincense-myrrh compound volatile oil and its preparation method and use Download PDFInfo
- Publication number
- CN102579548A CN102579548A CN201210050858XA CN201210050858A CN102579548A CN 102579548 A CN102579548 A CN 102579548A CN 201210050858X A CN201210050858X A CN 201210050858XA CN 201210050858 A CN201210050858 A CN 201210050858A CN 102579548 A CN102579548 A CN 102579548A
- Authority
- CN
- China
- Prior art keywords
- myrrha
- volatile oil
- olibanum
- compound volatile
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses frankincense-myrrh compound volatile oil and its preparation method and use. The preparation method of the frankincense-myrrh compound volatile oil comprises that crude frankincense and crude myrrh are mixed according to a weight ratio of (1: 50) to (50: 1) and the frankincense-myrrh compound volatile oil is extracted from the mixture. The frankincense-myrrh compound volatile oil can be extracted by a steam distillation technology, an organic solvent immersion extraction technology or a supercritical extraction technology. A result of an experiment shows that the frankincense-myrrh compound volatile oil has good effects of resisting isoprenaline-caused rat myocardial ischemia, protecting cardiocytes cultured in vitro from anoxia/reoxygenation, relieving angina and reducing angina attack frequency or reducing a pain degree in an angina attack, has treatment effects which are obviously better than treatment effects of crude frankincense-myrrh powder and a frankincense-myrrh water decoction, can be utilized for preparation of medicinal preparations for treating myocardial ischemia and/or angina, and especially can be utilized for preparation of a medicinal preparation for treating heart blood stasis-caused angina.
Description
Technical field
The present invention relates to a kind of Olibanum-Myrrha compound volatile oil, belong to technical field of Chinese medicines.
Background technology
Olibanum, Myrrha be clinical promoting blood circulation to remove blood stasis commonly used, reducing swelling and alleviating pain to medicine.Olibanum is the resin that olive subject plant Boswellia carterii and congener bark portion ooze out; Warm in nature, acrid in the mouth is bitter, has promoting blood circulation and stopping pain; The effect of detumescence and promoting granulation, main component for free a-boswellic acid, b-boswellic acid, combine boswellic acid and ferulic acid and amaroid, volatilization wet goods.Myrrha is the oleo-gum-resin that olive subject plant myrrh and congener stem skin zone ooze out, and property is flat, and bitter in the mouth has promoting blood circulation and stopping pain, and the effect of detumescence and promoting granulation, main component are resin, the volatile oil of natural gum.Modern pharmacological research shows that Olibanum, Myrrha have effects such as analgesic activity, antiinflammatory action, antioxidation, blood fat reducing, blood circulation promoting and blood stasis dispelling and antitumor.But mostly in the market is that the direct decocting in water of crude drug is used as medicine or crude drug powder is used as medicine, and the best agents area of medical material directly is not used as medicine, and existing document is not applied to treat the report of relevant diseases such as myocardial ischemia, angina pectoris yet about Olibanum, Myrrha.Therefore, be necessary the best agents area of Olibanum, Myrrha is extracted and develop its new application.
Summary of the invention
The purpose of this invention is to provide a kind of Olibanum-Myrrha compound volatile oil.
Olibanum of the present invention-Myrrha compound volatile oil, be by the Olibanum crude drug with after the Myrrha crude drug mixes by 1: 50～50: 1 weight ratios, extract volatile oil wherein and get.
As a kind of preferred version, described Olibanum-Myrrha compound volatile oil, be by the Olibanum crude drug with after the Myrrha crude drug mixes by 1: 1～10: 1 weight ratios, extract volatile oil wherein and get.
The method for preparing of a kind of described Olibanum-Myrrha compound volatile oil is at first crude drug Olibanum and crude drug Myrrha to be mixed, pulverize by proportioning, places volatile oil extraction equipment then, adopts steam distillation technology to extract volatile oil wherein.
As a kind of preferred version, when adopting steam distillation technology to extract, add water weight and be 0.1～50 times of medical material weight, the medical material soak time is 0～50 hour, each extraction time is 0.1～50 hour, extracts altogether 1～10 time.
As further preferred version, when adopting steam distillation technology to extract, add water weight and be 5～10 times of medical material weight, the medical material soak time is 0.5～5 hour, each extraction time is 5～10 hours, extracts altogether 1～5 time.
The preparation of described Olibanum-Myrrha compound volatile oil; Also can adopt following method: at first crude drug Olibanum and crude drug Myrrha are mixed, pulverize by proportioning; Place volatile oil extraction equipment then; Adopt the organic solvent soaking and extracting, fling to organic solvent then, promptly get described Olibanum-Myrrha compound volatile oil.
As a kind of preferred version, described organic solvent is selected from dehydrated alcohol, ether, ethyl acetate, the normal hexane one or more mixed solvent arbitrarily.
The preparation of described Olibanum-Myrrha compound volatile oil also can be adopted supercritical extraction process to extract and gets.
The application of described Olibanum-Myrrha compound volatile oil is meant that Olibanum-Myrrha compound volatile oil is used for preparation treatment myocardial ischemia and/or anginal pharmaceutical preparation with single form or with composition forms that pharmaceutically acceptable pharmaceutical carrier is formed.
As a kind of preferred version, the application of described Olibanum-Myrrha compound volatile oil is meant that Olibanum-Myrrha compound volatile oil is used for the anginal pharmaceutical preparation of preparation treatment heart arteries and veins blood stasis blocking type with single form or with composition forms that pharmaceutically acceptable pharmaceutical carrier is formed.
Described pharmaceutical dosage forms can be any pharmaceutically useful dosage form, and these dosage forms comprise: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, ointment, plaster, cream, spray, drop, patch drop pill, sublingual administration agent etc.; Take for the ease of the patient, improve preparation stability, be preferably drop pill, capsule and sublingual administration dosage form.
The present invention has following beneficial effect:
1) adopt effective site to be used as medicine, curative effect is more remarkable
The present invention makes up Olibanum volatile oil and Myrrha volatile oil; Make each efficacy of drugs produce synergism; Thereby can improve the various symptoms that cause coronary heart disease by stagnation of blood stasis through blood circulation promoting and blood stasis dispelling, promoting the circulation of QI to relieve pain; Pharmacological evaluation shows: Olibanum of the present invention-Myrrha compound volatile oil has antagonism preferably for the rat heart muscle ischemia that isoproterenol causes, and also has the better protect effect for the myocardial cell anoxia reoxygenation injury of In vitro culture; Experiment on probation shows through human body: Olibanum-Myrrha volatile oil share has analgesic effect preferably to angina pectoris; And the pain degree can reduce the angina pectoris attacks frequency or alleviate angina pectoris attacks the time, treat the anginal effect of heart arteries and veins blood stasis blocking type preferably thereby have; And therapeutic effect obviously is better than Olibanum-Myrrha crude drug powder and Olibanum-Myrrha decocting liquid.
2) preparation technology is easy, cost is low, be convenient to suitability for industrialized production.
Description of drawings
Fig. 1 is the ultrastructure figure of cardiac muscular tissue of the acute myocardial ischemia rat that is caused by isoproterenol of each experimental group among the embodiment 17, and wherein: a is a normal group; B is a model group; The positive medicine group of c; D is Olibanum-Myrrha compound volatile oil high dose group; E is a dose groups in Olibanum-Myrrha compound volatile oil; F is Olibanum-Myrrha compound volatile oil low dose group; G is Olibanum-Myrrha decocting liquid group; H is Olibanum-Myrrha crude drug powder group.
The specific embodiment
Below through embodiment and accompanying drawing to the present invention do further in detail, intactly explanation.
Embodiment 1
With weight ratio 1: 1 Olibanum and Myrrha; Pulverizing is placed in the volatile oil extraction equipment, adds water weight and be 8 times of medical material weight, and the medical material soak time is 1 hour; The steam extraction time is 8 hours; Extract altogether 1 time, collect and extract the volatile oil that obtains, be described Olibanum-Myrrha compound volatile oil.
Embodiment 2
With weight ratio 50: 1 Olibanum and Myrrha; Pulverizing is placed in the volatile oil extraction equipment, adds water weight and be 0.1 times of medical material weight, and the medical material soak time is 0 hour; Each steam extraction time is 0.1 hour; Extract altogether 10 times, collect and extract the volatile oil that obtains, be described Olibanum-Myrrha compound volatile oil.
Embodiment 3
With weight ratio 1: 50 Olibanum and Myrrha; Pulverizing is placed in the volatile oil extraction equipment, adds water weight and be 50 times of medical material weight, and the medical material soak time is 50 hours; The steam extraction time is 50 hours; Extract altogether 1 time, collect and extract the volatile oil that obtains, be described Olibanum-Myrrha compound volatile oil.
Embodiment 4
With weight ratio 10: 1 Olibanum and Myrrha; Pulverizing is placed in the volatile oil extraction equipment, adds water weight and be 25 times of medical material weight, and the medical material soak time is 25 hours; Each steam extraction time is 25 hours; Extract altogether 5 times, collect and extract the volatile oil that obtains, be described Olibanum-Myrrha compound volatile oil.
Embodiment 5
With weight ratio 1: 1 Olibanum and Myrrha; Pulverizing is placed in the volatile oil extraction equipment; Add the ether of 1～100 times of volume (ml) of medical material weight (g), carried out soaking and extracting 0.1～100 hour, fling to solvent then; Collect and extract the volatile oil that obtains, be described Olibanum-Myrrha compound volatile oil.
Embodiment 6
With weight ratio 1: 1 Olibanum and Myrrha; Pulverizing is placed in the supercritical extraction equipment; At pressure was 1～100MPa, and temperature is under 1～100 ℃ the condition, with co_2 supercritical fluid extraction 0.1～10 hour; Collect and extract the volatile oil that obtains, be described Olibanum-Myrrha compound volatile oil.
Embodiment 7
The Olibanum that makes-Myrrha compound volatile oil directly is loaded in the soft capsule, or adds to refill behind diluent, the stabilizing agent etc. and be stated from the soft capsule, can be prepared into the oral soft capsule dosage form.
Embodiment 8
The Olibanum that makes-Myrrha compound volatile oil directly is loaded in the hard capsule, or adds to refill behind diluent, the stabilizing agent etc. and be stated from the hard capsule, can be prepared into the oral hard capsule dosage form.
Embodiment 9
In the Olibanum that makes-Myrrha compound volatile oil, add the required pharmaceutical adjunct of preparation drop pill, can be prepared into the oral administration dripping pill dosage form.
Embodiment 10
In the Olibanum that makes-Myrrha compound volatile oil, add pharmaceutical adjuncts such as absorbent, excipient, can be prepared into the oral administration pills dosage form.
Embodiment 11
In the Olibanum that makes-Myrrha compound volatile oil, add pharmaceutical adjuncts such as absorbent, excipient, can be prepared into the oral tablet dosage form.
Embodiment 12
In the Olibanum that makes-Myrrha compound volatile oil, go into pharmaceutical adjuncts such as absorbent, excipient, can be prepared into the oral granular formulation dosage form.
Embodiment 13
In the Olibanum that makes-Myrrha compound volatile oil, add pharmaceutical adjuncts such as solubilizing agent, stabilizing agent, antiseptic, correctives, can be prepared into oral liquid formulation.
Embodiment 14
In the Olibanum that makes-Myrrha compound volatile oil, do not add or add pharmaceutical adjuncts such as diluent, solubilizing agent, stabilizing agent, antiseptic, can be prepared into oral drop dosage form.
Embodiment 15
In the Olibanum that makes-Myrrha compound volatile oil, add pharmaceutical adjuncts such as spray, spray-filming agent, cataplasma, paster, plaster, can be prepared into exterior-applied formulations such as spray, spray-filming agent, cataplasma, paster, plaster.
Embodiment 16
Prepared Olibanum-Myrrha compound volatile oil also can be prepared into sublingual administration dosage form, form of nose drops, injection type.
The zoopery of embodiment 17 Olibanums-Myrrha compound volatile oil
One, Olibanum-Myrrha compound volatile oil causes the influence of rat heart muscle ischemia to isoproterenol
Method: 64 of SD rats are divided into 8 groups at random.Through the method for lumbar injection isoproterenol, cause the acute myocardial ischemia model.Behind gastric infusion, measure the 30min electrocardio, detect the content of CK, AST, LDH in the serum; The ultrastructure of electron microscopy observation myocardial cell.
The influence of table 1 couple ∑ ST (Mean ± SD, n=8)
| Group | Dosage | ∑ST(mV) |
| Normal group | - | 0.105±0.022 |
| Model group | - | 1.272±0.035# |
| The positive drug group | 0.2g/kg | 0.471±0.221* |
| Olibanum-Myrrha compound volatile oil high dose group | 0.48g/kg | 0.624±0.149* |
| Dose groups in Olibanum-Myrrha compound volatile oil | 0.24g/kg | 0.658±0.144* |
| Olibanum-Myrrha compound volatile oil low dose group | 0.12g/kg | 0.668±0.147* |
| Olibanum-Myrrha decocting liquid group | 3.25g/kg | 0.869±0.102* |
| Olibanum-Myrrha crude drug powder group | 3.25g/kg | 0.891±0.021* |
Annotate: # and normal group compare, p＜0.05; * compare p＜0.05 with model group;
▲Compare p＜0.05 with Olibanum-Myrrha decocting liquid group, Olibanum-Myrrha crude drug powder group; Down together.
Visible by table 1: the ∑ ST of model group increases (p＜0.05) than normal group is obvious; Olibanum-high, normal, basic group of Myrrha compound volatile oil, Olibanum-Myrrha decocting liquid group, Olibanum-Myrrha crude drug powder group are compared with model group; ∑ ST obviously reduces; Difference has remarkable meaning (p＜0.05); But high, normal, basic group of Olibanum-Myrrha compound volatile oil is compared with Olibanum-Myrrha decocting liquid group, Olibanum-Myrrha crude drug powder group, and ∑ ST obviously reduces (p＜0.05), has shown better action effect.
The influence of table 2 couple CK, AST, LDH (Mean ± SD, n=8)
Visible by table 2: compare with normal group, model group serum CK, LDH, AST obviously increase (p＜0.05); Olibanum-high, normal, basic dose groups of Myrrha compound volatile oil and model group compare, and serum CK, LDH, AST obviously reduce (p＜0.05); The high, normal, basic dose groups serum CK of Olibanum-Myrrha volatile oil is compared with Olibanum-Myrrha decocting liquid group, Olibanum-Myrrha crude drug powder group, obviously lowers (p＜0.05); Dose groups serum AST compares with Olibanum-Myrrha decocting liquid group, Olibanum-Myrrha crude drug powder group in Olibanum-Myrrha compound volatile oil, obviously lowers (p＜0.05); The high low dose group Serum LDH of Olibanum-Myrrha volatile oil is compared with Olibanum-Myrrha decocting liquid group, Olibanum-Myrrha crude drug powder group, obviously lowers (p＜0.05); Thereby can show that Olibanum of the present invention-Myrrha compound volatile oil has better effect than Olibanum-Myrrha decocting liquid, Olibanum-Myrrha crude drug powder.
In addition, visible by Fig. 1: normal group (a figure) cardiac muscular tissue's myofilament marshalling, muscle segment light and shade band is clear; Nucleus is complete, and is rounded; Mitochondrial membrane is complete, and is rounded or oval, and mitochondrial crista is intensive to be laterally or vertically arrangement.Model group (b figure) cardiac muscular tissue's myofilament arrangement disorder, muscle segment shortens, and structure is unclear; Karyopyknosis, distortion, the kernel cracking; The obvious enlargement of mitochondrion, mitochondrial crista fracture dissolving forms big cavity or cavity.Cardiac muscular tissue's myofilament of positive group (c figure) and Olibanum-Myrrha compound volatile oil high dose group (d figure), middle dose groups (e figure) and low dose group (f figure) is arranged more neat, and muscle segment light and shade band is obvious; Nucleus is more complete, the kernel complete display; Mitochondrial membrane is complete, most rounded or ellipticity, and ridge is intensive, and cavity is less.And Olibanum-Myrrha compound volatile oil group compares with Olibanum-Myrrha decocting liquid group (g figure), Olibanum-Myrrha crude drug powder group (h figure), and myofilament is arranged more neat, and muscle segment light and shade band is obvious; Nucleus is more complete, the kernel complete display; Mitochondrial membrane is complete, further specifies Olibanum of the present invention-Myrrha compound volatile oil and has better myocardial cell protection effect.
Above experimental result shows: Olibanum of the present invention-Myrrha compound volatile oil has the significant protection effect to the rat heart muscle ischemia; Can significantly reduce the myocardial damage degree; Improve ischemic myocardium oxygen supply-aerobic unbalance state; Its mechanism possibly be through improving myocardial metabolism and morphological structure, alleviate multipath performance function of resisting myocardial ischemia such as the myocardial cell extent of damage, having better action effect than Olibanum-Myrrha decocting liquid, Olibanum-Myrrha crude drug powder.
Two, the protective effect of anoxia _ reoxygenation injury of myocardium cell is studied
Method: the neonatal rat myocardial cell of getting In vitro culture; Set up the anoxia _ reoxygenation myocardial cells damage model; Experiment is divided into 6 groups: normal serum matched group, model control group (H/R group), Olibanum-Myrrha compound volatile oil pastille serum group, Olibanum-Myrrha decocting liquid pastille serum group, Olibanum-Myrrha crude drug powder pastille serum group and positive drug (isosorbide mononitrate) serum group; Adopt the MTT colorimetry to detect the injury of myocardium cell survival rate, and measure endochylema malonaldehyde (MDA) content and superoxide dismutase (SOD) activity.
Table 3 respectively organize the myocardial cell survival rate (Mean ± SD, n=6)
| Group | Survival rate (%) | LDH(U/L) |
| Normal group | 100 | 548.24±45.38 |
| Model group | 50.50±0.72 # | 1024.65±7.55 # |
| Olibanum-Myrrha compound volatile oil group | 66.42±4.56* | 768.87±20.24* |
| Olibanum-Myrrha decocting liquid group | 62.41±3.78* | 861.87±21.15* |
| Olibanum-Myrrha crude drug powder group | 60.30±4.05* | 832.87±19.34* |
| The isosorbide mononitrate group | 75.14±2.38* | 749.16±3.43* |
Annotate: compare with normal group,
#P＜0.01; Compare * p＜0.01 with model group;
▲Compare p＜0.05 with Olibanum-Myrrha decocting liquid group, Olibanum-Myrrha crude drug powder group; Down together.
Visible by table 3: with compared with normal, H/R group neonatal rat myocardial cell survival rate obviously reduces (P＜0.01), and model group LDH leakage showed increased (p＜0.01) explains that myocardial cell damages; Compare with model group, the survival rate of Olibanum-Myrrha compound volatile oil group, Olibanum-Myrrha decocting liquid group, Olibanum-Myrrha crude drug powder group myocardial cell obviously increases (p＜0.05), the LDH leakage obviously reduces (p＜0.05); Olibanum-Myrrha compound volatile oil group is compared with Olibanum-Myrrha decocting liquid group, Olibanum-Myrrha crude drug powder group, and the myocardial cell survival rate obviously increases (p＜0.05), the LDH leakage obviously reduces (p＜0.05), and Olibanum-Myrrha compound volatile oil group better effects if is described.
Table 4 respectively organize SOD activity and MDA content (Mean ± SD, n=6)
| Group | MDA(nmol/mgprot) | SOD(U/mgprot) |
| Normal group | 4.98±0.21 | 112.12±0.76 |
| Model group | 13.11±0.42# | 53.51±1.46# |
| Olibanum-Myrrha compound volatile oil group | 7.15±0.29* | 85.89±1.28* |
| Olibanum-Myrrha decocting liquid group | 8.78±0.31* | 62.35±1.18* |
| Olibanum-Myrrha crude drug powder group | 8.42±0.34* | 63.78±1.18* |
| The isosorbide mononitrate group | 7.36±0.14* | 85.16±1.20* |
Visible by table 4: with compared with normal, model group MDA content raises, active reduce (p＜0.05) of SOD, explains that the model group oxidation resistance reduces.Compare with model group, the MDA content of Olibanum-Myrrha compound volatile oil group, Olibanum-Myrrha decocting liquid group and Olibanum-Myrrha crude drug powder group reduces, SOD increased activity (p＜0.05); Olibanum-Myrrha compound volatile oil group is compared with Olibanum-Myrrha decocting liquid group, Olibanum-Myrrha crude drug powder group, and MDA content reduces, SOD increased activity (p＜0.05), and Olibanum-Myrrha compound volatile oil better effects if is described.
Above experimental result shows: Olibanum of the present invention-Myrrha compound volatile oil can be through the protection cell membrane integrity; Enhancing body is to the removing ability of oxygen-derived free radicals; Alleviate cell membrane lipid peroxide injury; Thereby performance is to the protective effect of myocardial cell anoxia _ reoxygenation damage, and effect is better than Olibanum-Myrrha decocting liquid and Olibanum-Myrrha crude drug powder.
Embodiment 18
Choose 18 routine angina pectoris patients; Its angina pectoris belongs to heart arteries and veins blood stasis blocking type, when angina pectoris takes place, by taking Olibanum of the present invention-Myrrha compound volatile oil 1.5g/ people/day; The result shows: can obviously alleviate the angina pectoris degree, and can alleviate occur together uncomfortable in chest, symptom such as breathe hard.Press 1.5g/ people/day, take Olibanum of the present invention-Myrrha compound volatile oil for three days on end, the result shows: the pain degree in the time of can obviously reducing the frequency of angina pectoris attacks or alleviate outbreak.
Be necessary at last to be pointed out that at this: above embodiment only is used for technical scheme of the present invention is done further explain; Can not be interpreted as the restriction to protection domain of the present invention, some nonessential improvement that those skilled in the art's foregoing according to the present invention is made and adjustment all belong to protection scope of the present invention.
Claims (10)
1. Olibanum-Myrrha compound volatile oil is characterized in that: be by the Olibanum crude drug with after the Myrrha crude drug mixes by 1: 50～50: 1 weight ratios, extract volatile oil wherein and get.
2. the method for preparing of the described Olibanum of claim 1-Myrrha compound volatile oil; It is characterized in that: be at first crude drug Olibanum and crude drug Myrrha to be mixed, pulverize by proportioning; Place volatile oil extraction equipment then, adopt steam distillation technology to extract volatile oil wherein.
3. the method for preparing of Olibanum according to claim 2-Myrrha compound volatile oil; It is characterized in that: when adopting steam distillation technology to extract; Add water weight and be 0.1～50 times of medical material weight; The medical material soak time is 0～50 hour, and each extraction time is 0.1～50 hour, extracts altogether 1～10 time.
4. the method for preparing of Olibanum according to claim 3-Myrrha compound volatile oil; It is characterized in that: when adopting steam distillation technology to extract, add water weight and be 5～10 times of medical material weight, the medical material soak time is 0.5～5 hour; Each extraction time is 5～10 hours, extracts altogether 1～5 time.
5. the method for preparing of the described Olibanum of claim 1-Myrrha compound volatile oil is characterized in that: be at first crude drug Olibanum and crude drug Myrrha to be mixed, pulverize by proportioning, adopt organic solvent soaking and extracting technology to extract the volatile oil in the mixed medicinal materials then.
6. the method for preparing of Olibanum according to claim 5-Myrrha compound volatile oil is characterized in that: described organic solvent is selected from dehydrated alcohol, ether, ethyl acetate, the normal hexane one or more mixed solvent arbitrarily.
7. the method for preparing of the described Olibanum of claim 1-Myrrha compound volatile oil is characterized in that: be at first crude drug Olibanum and crude drug Myrrha to be mixed, pulverize by proportioning, adopt supercritical extraction process to extract the volatile oil in the mixed medicinal materials then.
8. the application of the described Olibanum of claim 1-Myrrha compound volatile oil is characterized in that: described Olibanum-Myrrha compound volatile oil is used for preparation treatment myocardial ischemia and/or anginal pharmaceutical preparation with single form or with composition forms that pharmaceutically acceptable pharmaceutical carrier is formed.
9. the application of Olibanum according to claim 8-Myrrha compound volatile oil is characterized in that: described Olibanum-Myrrha compound volatile oil is used for the anginal pharmaceutical preparation of preparation treatment heart arteries and veins blood stasis blocking type with single form or with composition forms that pharmaceutically acceptable pharmaceutical carrier is formed.
10. according to Claim 8 or the application of 9 described Olibanum-Myrrha compound volatile oils, it is characterized in that: described pharmaceutical preparation is meant drop pill, capsule and sublingual administration agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210050858XA CN102579548A (en) | 2012-02-29 | 2012-02-29 | Frankincense-myrrh compound volatile oil and its preparation method and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210050858XA CN102579548A (en) | 2012-02-29 | 2012-02-29 | Frankincense-myrrh compound volatile oil and its preparation method and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102579548A true CN102579548A (en) | 2012-07-18 |
Family
ID=46469150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210050858XA Pending CN102579548A (en) | 2012-02-29 | 2012-02-29 | Frankincense-myrrh compound volatile oil and its preparation method and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102579548A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106753795A (en) * | 2016-12-11 | 2017-05-31 | 钦州学院 | The preparation method of myrrh essential oil |
| CN107029147A (en) * | 2017-06-01 | 2017-08-11 | 泉州医学高等专科学校 | A kind of preparation technology of the sweet compound dripping pill agent of Chinese herbaceous peony |
| CN107184866A (en) * | 2017-06-01 | 2017-09-22 | 泉州医学高等专科学校 | A kind of preparation technology of the sweet compound capsule of Chinese herbaceous peony |
-
2012
- 2012-02-29 CN CN201210050858XA patent/CN102579548A/en active Pending
Non-Patent Citations (4)
| Title |
|---|
| 《山东中医杂志》 20041031 李峰等 乳香没药的超临界CO2萃取工艺研究 第623-625页 1，5-7 第23卷, 第10期 * |
| 李峰等: "乳香没药的超临界CO2萃取工艺研究", 《山东中医杂志》 * |
| 殷玉生等: "乳香炮制方法的探讨", 《中药通报》 * |
| 郑杭生等: "乳香没药的提取工艺及其提取物的镇痛作用", 《中成药》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106753795A (en) * | 2016-12-11 | 2017-05-31 | 钦州学院 | The preparation method of myrrh essential oil |
| CN107029147A (en) * | 2017-06-01 | 2017-08-11 | 泉州医学高等专科学校 | A kind of preparation technology of the sweet compound dripping pill agent of Chinese herbaceous peony |
| CN107184866A (en) * | 2017-06-01 | 2017-09-22 | 泉州医学高等专科学校 | A kind of preparation technology of the sweet compound capsule of Chinese herbaceous peony |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101812746B1 (en) | Formulations containing extracts of echinacea angustifolia and zingiber officinale which are useful in reducing inflammation and peripheral pain | |
| US20080152736A1 (en) | Lipid Fraction of Nigella Sativa L. Seeds | |
| WO2013000382A1 (en) | Fatty acid composition and plant extract and pharmaceutical preparation and application thereof | |
| KR20200063855A (en) | A composition for promoting melanin synthesis comprising flower extract of milk thistle | |
| CN105582383A (en) | Composition containing alkannin and lemon grass essential oil | |
| WO2014118040A1 (en) | Extract from indigo tinctoria for the topical treatment and prophylaxis of skin disorders | |
| CN102579548A (en) | Frankincense-myrrh compound volatile oil and its preparation method and use | |
| KR102542842B1 (en) | How to relieve the symptoms of PMS | |
| US11446277B2 (en) | Penetrating pain relief cream | |
| CN105030864A (en) | Transdermal delivered pharmaceutical composition with pain reliving and inflammation preventing effects, applications and preparation method thereof | |
| KR20190049529A (en) | Composition | |
| KR102610339B1 (en) | Uses of Buliaconitin A | |
| CN105796654B (en) | Traditional Chinese medicine composition for treating diarrhea-predominant irritable bowel syndrome, navel patch and application | |
| ES2377612B1 (en) | USE OF CRASSULA FOR THE TREATMENT OF PROLIFERATIVE DISEASES. | |
| CN101933963B (en) | Nasal in-situ gel for treating headache | |
| KR20210119804A (en) | Compositions for reinforcing skin barrier and improving atopic dermatitis using an extract of wild edible greens as an active ingredient | |
| CN109350632A (en) | A kind of Chinese medicine composition for antipyretic-antalgic | |
| CN101623286B (en) | Transdermal administration composite containing cucurbitacin-type active ingredient | |
| TW201309317A (en) | An extract of plant providing for treating the healing of wounds | |
| KR102167530B1 (en) | Composition comprising plant extract effective for skin health | |
| CN111298075B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN110384785B (en) | A topical Chinese medicinal liquid for treating viral common cold, and its preparation method | |
| CN104510809B (en) | Garden burnet or its extract novel anti-virus purposes | |
| CN101612203B (en) | Traditional Chinese medicine composition used for treating pointed condyloma and application thereof | |
| CN106466261A (en) | Health preserving skin care compositionss |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120718 |